Back to top

Verastem’s KRAS G12D Trial Targets a New Niche in Colorectal Cancer

Verastem Inc ($VSTM) announced an update on their ongoing clinical study. The phase 2 TARGET-D 203 study from Verastem, Inc. focuses on patients wi...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Verastem, Inc. (VSTM)